Dr Aravindhan Sundaramurthy 06071048

Clinical oncology


  • Fee assured

About me

I am a consultant in clinical oncology specialising in genitourinary cancers. I offer systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted oral therapies, novel anti-hormonal agents) and radiation therapy for cancers of prostate, bladder, kidney and penis.

I have a special interest in radiotherapy, both external beam radiotherapy (image guided IMRT/VMAT) and brachytherapy (LDR “seed” brachytherapy and HDR brachytherapy). There is growing evidence that increasing the radiation dose to prostate in localised disease can improve cancer cure rates. This is particularly relevant to cancers with unfavourable features. I do LDR “seed” brachytherapy as a monotherapy in favourable prostate cancers as well as a “boost” to image guided volumetric arc therapy (VMAT) in patients with unfavourable features.

I strongly believe, in localised prostate cancers, we should channel our research resources towards minimising the harms of treatment by considering protocols for focal tumour treatments, biomarker driven selection of patients for treatment dose escalation and maximise dose escalation in high-risk patients with advanced radiotherapy techniques. Prior to my appointment as a consultant at Edinburgh, I did a clinical and research fellowship in genitourinary malignancies and prostate brachytherapy at the Princess Margaret Cancer Centre. I was awarded the CARO-ACURA 2017 grant for a focal dose escalation study in prostate cancer using MRI-guided HDR-brachytherapy boost to tumour while delivering SBRT to the whole gland.

I am currently leading a case for high-dose-rate (HDR) brachytherapy at the ECC and I eagerly anticipate starting this service over the next few months.

Systemic anti-cancer therapies are rapidly evolving in genitourinary cancers, with newer and existing agents getting approved for use in different stages of cancers. I have an extensive experience in systemic therapies, using,

• Chemotherapy agents such as Docetaxel, Platinum based agents
• Immunotherapy agents such as Ipilimumab, Nivolumab, Pembrolizumab
• Oral TKIs such as sunitinib, pazopanib, tivozanib, cabozantinib or axitinib
• Novel agents such as abiraterone, enzalutamide, alpharadin

As a scientific member of the national cancer research institute (ncri) prostate cancer subgroup, I work towards bringing in national and international trials in genitourinary cancers to the southeast Scotland cancer network (SCAN).

Areas of interest

Prostate cancer, Renal cancer, Bladder cancer, Penile cancer, Radiotherapy, Brachytherapy, Chemotherapy,Immunotherapy, TKIs, novel anti-hormonal agents

Medical secretaries

My qualifications & training
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0003

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)

    Spire Murrayfield Hospital Edinburgh (5-50)

  • X0004

    Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)

    Spire Murrayfield Hospital Edinburgh (1-5)

  • BT212

    Insertion of low dose radioactive agent (brachytherapy) into prostate tumour - (1-5)

Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.